14 August 2001
Continuous alloantigen elimination--a concept for allograft tolerancer.
W L OlszewskiAnn Transplant 2000; 5(4): 14-19 :: ID: 607130
Abstract
The "enhancement" phenomenon evoked in rats by administration of donor lymphocytes and recipient-anti-donor-lymphocyte antibodies prior to organ transplantation brings about "continuous alloantigen elimination". This new concept is based on the experimental data from studies on the distribution of radiolabelled alloantigen and alloantibody in the recipient lymphoid organs and suggests that immediately after organ transplantation to the "enhanced" recipient, the circulating antibodies bind to the donor transplantation antigens both on endothelial cells and those shed into recipient blood circulation. The formed alloantigen-alloantibody complexes are trapped in the spleen and after opsonization and binding to the migrating splenocytes are transported to the liver for further processing. The process of continuous binding of alloantigen and elimination as alloantibody-alloantigen complexes in the lymphoid organs of the recipient prevents activation of the recipient effector cells and their migration to the graft. The organ grafts survive above 100 days. Although there is no evident rejection in the allograft itself a phenomenon of "rejection alert" is seen in the lymphoid tissue. The lymphocytes originating from the organ graft donor injected intravenously are rejected in the "enhanced" recipient spleen and nodes within 6 hours. The "physiological" site of elimination (rejection) of alloantigens are the lymphoid organs, as it happens with invading pathogens. The allotransplant is spared since its alloantigens are "blocked" by anti-donor-specific antibodies, the complexes are continuously detached and washed-off by the percolating blood and eliminated in the lymphoid tissues and liver.
Keywords: Antigen-Antibody Complex - metabolism, Graft Survival - immunology, Heart Transplantation - immunology, Immune Tolerance, Isoantibodies - metabolism, Isoantigens - metabolism, Lymphoid Tissue - metabolism, Skin Transplantation - immunology, Transplantation Immunology, Transplantation, Homologous
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






